AZ PHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
AZ PHARMA
Largest movements
- Tangible fixed assets -€37,969
down €37,969 (-10.7%), from €356,075 to €318,106
- Profit (loss) carried forward +€90,213
up €90,213 (+799.3%), from €11,286 to €101,500
- Debts after one year -€71,382
down €71,382 (-11.4%), from €627,780 to €556,398
- Other debts -€56,580
down €56,580 (-7.7%), from €733,059 to €676,479
- Depreciation +€37,969
new in 2025: €37,969
- Financial income +€20,500
up €20,500 (+17.8%), from €115,000 to €135,500
- Financial charges -€11,042
down €11,042 (-40.8%), from €27,031 to €15,990
- Gross operating margin +€2,940
up €2,940 (+35.4%), from €8,298 to €11,239
- Other operating charges +€2,567
new in 2025: €2,567
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,458,311 | €1,418,241 | -€40,070 | -2.7% |
| Fixed assets | 21/28 | €1,456,075 | €1,418,106 | -€37,969 | -2.6% |
| Tangible fixed assets | 22/27 | €356,075 | €318,106 | -€37,969 | -10.7% |
| Land and buildings | 22 | €356,075 | €318,106 | -€37,969 | -10.7% |
| Financial fixed assets | 28 | €1,100,000 | €1,100,000 | = | 0.0% |
| Current assets | 29/58 | €2,236 | €135 | -€2,101 | -94.0% |
| Cash at bank and in hand | 54/58 | €2,236 | - | -€2,236 | |
| Deferred charges and accrued income | 490/1 | - | €135 | +€135 | |
| Total equity and liabilities | 10/49 | €1,458,311 | €1,418,241 | -€40,070 | -2.7% |
| Equity | 10/15 | €25,286 | €115,500 | +€90,213 | +356.8% |
| Contributions | 10/11 | €14,000 | €14,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €11,286 | €101,500 | +€90,213 | +799.3% |
| Amounts payable | 17/49 | €1,433,025 | €1,302,741 | -€130,283 | -9.1% |
| Amounts payable after more than one year | 17 | €627,780 | €556,398 | -€71,382 | -11.4% |
| Financial debts | 170/4 | €627,780 | €556,398 | -€71,382 | -11.4% |
| Amounts payable within one year | 42/48 | €805,244 | €746,343 | -€58,901 | -7.3% |
| Current portion of amounts payable after more than one year | 42 | €69,463 | €69,382 | -€81 | -0.1% |
| Trade debts | 44 | €2,722 | €482 | -€2,240 | -82.3% |
| Suppliers | 440/4 | €2,722 | €482 | -€2,240 | -82.3% |
| Other amounts payable | 47/48 | €733,059 | €676,479 | -€56,580 | -7.7% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | - | €37,969 | +€37,969 | |
| Other operating charges | 640/8 | - | €2,567 | +€2,567 | |
| Gross operating margin | 9900 | €8,298 | €11,239 | +€2,940 | +35.4% |
| Operating profit (loss) | 9901 | €8,298 | -€29,297 | -€37,595 | |
| Financial income | 75/76B | €115,000 | €135,500 | +€20,500 | +17.8% |
| Recurring financial income | 75 | €115,000 | €135,500 | +€20,500 | +17.8% |
| Financial charges | 65/66B | €27,031 | €15,990 | -€11,042 | -40.8% |
| Recurring financial charges | 65 | €27,031 | €15,990 | -€11,042 | -40.8% |
| Profit (loss) for the period before taxes | 9903 | €96,267 | €90,213 | -€6,054 | -6.3% |
| Profit (loss) for the period | 9904 | €96,267 | €90,213 | -€6,054 | -6.3% |
| Profit (loss) for the period to be appropriated | 9905 | €96,267 | €90,213 | -€6,054 | -6.3% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 8 October 2026 via checked.be.